Breaking News
Gyre Therapeutics (GYRE) Posts Q4 FY25 Loss of $0.02; misses estimates
Gyre Therapeutics posts $0.05 EPS vs $0.01 estimate on $37.2M revenue, guides fiscal 2026 to $100.5M-$111M.